+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rabies Immunoglobulins Market by Type (Equine, Human), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), End User, Route of Administration - Global Forecast 2025-2030- Product Image
Rabies Immunoglobulins Market by Type (Equine, Human), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), End User, Route of Administration - Global Forecast 2025-2030- Product Image
New

Rabies Immunoglobulins Market by Type (Equine, Human), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), End User, Route of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6127143
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Rabies immunoglobulins represent a critical line of defense in post-exposure prophylaxis, offering passive immunity to individuals at risk of this fatal neurological disease. This executive summary introduces the core themes and insights of a comprehensive analysis that examines production technologies, clinical adoption patterns, regulatory influences, and evolving market dynamics. An overview of the immunoglobulin supply chain reveals the interplay between plasma sourcing, purification processes, and stringent quality control measures that ensure patient safety and therapeutic efficacy. Transitioning from fundamental principles to strategic considerations, this section sets the stage for deeper exploration of market transformations and the factors that will shape future growth trajectories.

Comprehensive Exploration of Technological Breakthroughs and Regulatory Harmonization Driving a New Era in Rabies Immunoglobulin Development

The rabies immunoglobulin landscape has experienced transformative shifts driven by technological advances and evolving clinical best practices. Emerging cell culture methods have reduced reliance on animal-derived products, resulting in higher purity formulations with improved safety profiles. Concurrently, advances in adjuvant science and combination therapies have enhanced the immunogenic potential of certain immunoglobulin preparations, spurring research collaborations between biotech firms and academic institutions. Regulatory harmonization initiatives across major markets have also streamlined approval pathways, enabling companies to launch new products more quickly and align labeling standards.

At the same time, digital health platforms have begun to integrate inventory tracking and cold-chain monitoring for immunoglobulin shipments, enhancing visibility and reducing wastage. These developments are further complemented by growing patient awareness campaigns, which have elevated demand for post-exposure prophylaxis in endemic regions. As a result, manufacturers are refocusing R&D efforts on next-generation monoclonal and recombinant antibodies, aiming to address unmet needs such as improved half-life and broader neutralization profiles. Overall, these transformative trends are converging to reshape the competitive landscape and inform strategic decision-making across the value chain.

In-Depth Assessment of How Upcoming United States Trade Measures Will Reshape Supply Chain Economics and Sourcing Strategies in Rabies Immunoglobulin

Anticipated tariff adjustments in the United States for 2025 are poised to influence cost structures and global supply logistics for rabies immunoglobulins. Import duties on bulk human immunoglobulin concentrate and specialized manufacturing equipment could elevate input costs for domestic producers, prompting potential realignment of sourcing strategies toward local plasma collection and processing facilities. Consequently, manufacturers may increase forward integration efforts to mitigate margin pressures and secure capacity within U.S. borders. Meanwhile, distributors reliant on imported inventory could face inventory replenishment delays and incur higher warehousing expenses due to extended supply chains.

These cumulative impacts will likely accelerate collaborative ventures between U.S. and international entities to balance cost efficiencies with regulatory compliance. Forward-thinking stakeholders may explore toll manufacturing agreements and contract partnerships that leverage regional capabilities. Additionally, pricing strategies will require careful recalibration to protect accessibility for underserved populations. By proactively assessing tariff implications, industry leaders can develop resilient procurement frameworks and maintain continuity of post-exposure treatments during periods of policy transition.

Strategic Analysis of Market Dynamics Driven by Product Type, Distribution Channel Choices, Clinical End Users, and Administration Routes

A nuanced understanding of segment-specific demand patterns reveals clear distinctions across type, distribution channel, end user, and administration route. When analyzing products by type, two primary sources emerge: equine derivatives and human-derived immunoglobulins. Equine immunoglobulins continue to serve markets with limited cold-chain infrastructure, whereas human-derived formulations are favored in advanced healthcare settings for their reduced risk of hypersensitivity. Distribution channels encompass hospital pharmacies-both public and private-and retail outlets including chain and independent pharmacies, with online platforms gradually carving out a share through home delivery services.

End users span government and private clinics as well as public and private hospitals, each characterized by differing procurement cycles, budget constraints, and patient volume considerations. Clinics often prioritize cost-effective equine products for community outreach programs, while tertiary care hospitals invest in high-purity human immunoglobulins for comprehensive trauma care. Administration routes further refine market segmentation; topical infiltration remains the method of choice for precise wound-site neutralization, whereas intramuscular injections are widely used for systemic prophylaxis. Integrating these insights enables companies to tailor product portfolios, optimize channel strategies, and align distribution investments with evolving clinical demand.

Holistic Evaluation of Regional Healthcare Infrastructure Variability Shaping Rabies Immunoglobulin Access Across Major Global Markets

Regional variances are pronounced across the Americas, Europe Middle East and Africa, and Asia Pacific. In the Americas, well-established plasma donation networks and advanced manufacturing hubs underpin a robust immunoglobulin industry, though reimbursement policies and rural healthcare access remain ongoing challenges. Within Europe Middle East and Africa, regulatory convergence under the European Medicines Agency has facilitated product approvals, while emerging markets in the Middle East and North Africa are investing in domestic capacity to reduce import dependence.

Asia Pacific showcases a dual narrative of rapid growth in high-volume markets such as India and China, alongside nascent healthcare infrastructure in parts of Southeast Asia and the Pacific Islands. Government-led public health initiatives and international aid programs have accelerated post-exposure prophylaxis coverage, yet logistical hurdles persist in remote regions with limited cold-chain capabilities. Cross-regional partnerships are increasingly common, with technology transfers and joint ventures enabling local production of high-quality immunoglobulin. By appreciating these geographic nuances, stakeholders can calibrate supply chain models, navigate local regulatory environments, and align commercialization efforts with region-specific healthcare priorities.

Exhaustive Insight into Competitive Strategies and Technological Collaborations Driving Leadership and Differentiation Among Rabies Immunoglobulin Producers

Key players in the rabies immunoglobulin space are pursuing diverse strategies to strengthen their market position. Some multinational firms are investing in recombinant antibody research to develop next-generation prophylactic candidates with optimized pharmacokinetics. Others are forging alliances with academic institutions to validate novel manufacturing platforms that promise lower production costs and higher batch consistency. Contract manufacturing organizations have also expanded their service offerings, integrating end-to-end capabilities from plasma collection oversight to final fill-finish operations.

Competitive differentiation is increasingly grounded in service excellence, with select companies offering digital tools for inventory management, clinician training programs, and patient support initiatives. In parallel, mid-sized regional producers are leveraging local market knowledge to secure government tenders and establish preferential pricing agreements. Strategic M&A activity remains a focal point, as larger entities seek to acquire niche biologics firms with specialized immunoglobulin pipelines. Through these concerted efforts, industry participants are positioning themselves to meet evolving clinical expectations and address potential supply constraints.

Actionable Blueprint for Enhancing Manufacturing Agility, Strengthening Supply Resilience, and Expanding Market Reach in Rabies Immunoglobulin

Industry leaders must adopt a proactive posture to navigate emerging challenges and capitalize on new opportunities. First, investing in flexible manufacturing platforms will facilitate quick response to tariff-related disruptions and enable production scaling in target regions. Second, establishing strategic alliances with local plasma centers can secure supply continuity while fostering compliance with evolving regulatory frameworks. Third, incorporating lifecycle management plans that include next-generation monoclonal or recombinant assets can diversify product portfolios and extend revenue streams.

Moreover, enhancing digital infrastructure for real-time inventory visibility and cold-chain monitoring will reduce waste and improve distribution reliability. Engaging in stakeholder education programs-spanning healthcare providers, policymakers, and patient advocacy groups-can elevate awareness of the importance of timely prophylaxis. Finally, aligning pricing models with country-specific reimbursement landscapes and exploring innovative financing mechanisms will ensure affordability and equitable access. By acting on these recommendations, leaders can safeguard supply resilience, drive competitive differentiation, and ultimately improve patient outcomes.

Transparent Multi-Source Research Approach Combining Expert Interviews, Data Triangulation, and Segmentation Frameworks to Ensure Robustly Validated Insights

This study employed a multi-pronged methodology combining primary interviews with industry veterans, secondary literature reviews, and quantitative data validation. Primary research involved in-depth discussions with executives spanning vaccine developers, plasma fractionators, hospital procurement managers, and regulatory authorities to capture firsthand perspectives on technological trends, pricing pressures, and policy shifts. Secondary sources included peer-reviewed journals, government health agency reports, and publicly available corporate filings to corroborate qualitative insights and ensure methodological rigor.

A structured data triangulation approach was implemented, wherein multiple data points were cross-verified to reconcile any discrepancies. Segmentation frameworks were developed based on product type, distribution channel, end user, and route of administration to reflect real-world market differentiation. Regional analyses leveraged macroeconomic indicators, healthcare expenditure patterns, and epidemiological data to contextualize market dynamics. The resultant insights underwent iterative validation with subject matter experts to refine interpretations and solidify the report’s strategic recommendations.

Conclusive Synthesis of Key Trends, Strategic Imperatives, and Evolving Innovations Guiding the Future Direction of Rabies Immunoglobulin Markets

This executive summary has synthesized critical insights into the evolving realm of rabies immunoglobulins, from cutting-edge manufacturing techniques and regulatory developments to market segmentation nuances and regional disparities. By examining tariff implications, competitive strategies, and strategic recommendations, we have outlined a comprehensive perspective that informs strategic decision-making and highlights areas for operational enhancement. As the industry advances towards recombinant and monoclonal solutions, the ability to adapt manufacturing practices, optimize distribution channels, and engage stakeholders will determine which organizations emerge as market leaders.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Equine
    • Human
  • Distribution Channel
    • Hospital Pharmacy
      • Private Hospital Pharmacy
      • Public Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
      • Chain Retail Pharmacy
      • Independent Retail Pharmacy
  • End User
    • Clinics
      • Government Clinics
      • Private Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
  • Route Of Administration
    • Infiltration
    • Intramuscular
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Sanofi Pasteur SA
  • Grifols, S.A.
  • Kedrion S.p.A.
  • CSL Behring LLC
  • Serum Institute of India Private Limited
  • Bharat Serums and Vaccines Limited
  • Shandong Institute of Biological Products Co., Ltd.
  • Chengdu Institute of Biological Products Co., Ltd.
  • VINS Bioproducts Limited
  • The Egyptian Holding Company for Biological Products and Vaccines (Vacsera)

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of human monoclonal antibody alternatives to rabies immunoglobulin in post-exposure prophylaxis regimens driven by safety and supply advantages
5.2. Strategic collaborations between biopharmaceutical companies and global health agencies to expand rabies immunoglobulin access in underserved Asia-Pacific regions
5.3. Implementation of advanced continuous manufacturing processes to boost global rabies immunoglobulin production capacity and reduce batch variability
5.4. Increasing regulatory approvals for biosimilar immunoglobulin formulations creating competitive pricing pressures in key markets
5.5. Innovative plant-based expression systems emerging as cost-effective platforms for large-scale rabies antibody production
5.6. Challenges in maintaining cold chain logistics in low-resource settings impacting rabies immunoglobulin distribution and patient compliance
5.7. Growing investment in monoclonal versus polyclonal rabies immunoglobulin development pipelines due to scalability and consistency benefits
5.8. Impact of global plasma donation shortages on rabies immunoglobulin supply chains and strategic sourcing initiatives by manufacturers
5.9. Integration of digital temperature monitoring and IoT-enabled devices to ensure quality control of rabies immunoglobulin during transportation
5.10. Government-led procurement policies and tiered pricing models shaping affordability of rabies immunoglobulins in emerging economies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Rabies Immunoglobulins Market, by Type
8.1. Introduction
8.2. Equine
8.3. Human
9. Rabies Immunoglobulins Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.2.1. Private Hospital Pharmacy
9.2.2. Public Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.4.1. Chain Retail Pharmacy
9.4.2. Independent Retail Pharmacy
10. Rabies Immunoglobulins Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Government Clinics
10.2.2. Private Clinics
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
11. Rabies Immunoglobulins Market, by Route of Administration
11.1. Introduction
11.2. Infiltration
11.3. Intramuscular
12. Americas Rabies Immunoglobulins Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Rabies Immunoglobulins Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Rabies Immunoglobulins Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Sanofi Pasteur SA
15.3.2. Grifols, S.A.
15.3.3. Kedrion S.p.A.
15.3.4. CSL Behring LLC
15.3.5. Serum Institute of India Private Limited
15.3.6. Bharat Serums and Vaccines Limited
15.3.7. Shandong Institute of Biological Products Co., Ltd.
15.3.8. Chengdu Institute of Biological Products Co., Ltd.
15.3.9. VINS Bioproducts Limited
15.3.10. The Egyptian Holding Company for Biological Products and Vaccines (Vacsera)
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. RABIES IMMUNOGLOBULINS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. RABIES IMMUNOGLOBULINS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. RABIES IMMUNOGLOBULINS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. RABIES IMMUNOGLOBULINS MARKET: RESEARCHAI
FIGURE 24. RABIES IMMUNOGLOBULINS MARKET: RESEARCHSTATISTICS
FIGURE 25. RABIES IMMUNOGLOBULINS MARKET: RESEARCHCONTACTS
FIGURE 26. RABIES IMMUNOGLOBULINS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RABIES IMMUNOGLOBULINS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY EQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CHAIN RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CHAIN RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INDEPENDENT RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY GOVERNMENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INFILTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RABIES IMMUNOGLOBULINS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 95. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 96. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 97. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 100. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 101. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 102. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 103. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 106. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 107. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 108. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 109. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 112. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 113. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 116. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 117. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 118. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 119. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 194. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 195. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 200. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 201. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 210. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 211. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 214. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 215. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 216. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 217. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 242. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 243. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 246. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 247. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 248. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 249. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 252. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 253. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 258. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 259. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 262. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 263. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 290. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 306. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 310. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA RABIES IMMUNOGLOBULINS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 321. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 322. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 323. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 326. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 327. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 328. DENMARK RABIES IMMUNOGLOBULINS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Rabies Immunoglobulins market report include:
  • Sanofi Pasteur SA
  • Grifols, S.A.
  • Kedrion S.p.A.
  • CSL Behring LLC
  • Serum Institute of India Private Limited
  • Bharat Serums and Vaccines Limited
  • Shandong Institute of Biological Products Co., Ltd.
  • Chengdu Institute of Biological Products Co., Ltd.
  • VINS Bioproducts Limited
  • The Egyptian Holding Company for Biological Products and Vaccines (Vacsera)

Related Topics

Related Reports

Human Rabies Immunoglobulin Market by Application (Post Exposure Prophylaxis, Pre Exposure Prophylaxis), Formulation (Freeze Dried, Liquid), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Human Rabies Immunoglobulin Market by Application (Post Exposure Prophylaxis, Pre Exposure Prophylaxis), Formulation (Freeze Dried, Liquid), Route of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Rabies Immunoglobulins - Pipeline Insight, 2025 - Product Image

Rabies Immunoglobulins - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Human Rabies Immunoglobulin Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Human Rabies Immunoglobulin Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 97 Pages
  • Global
From
Hyperimmune Globulin Injection Market by Indication (Diphtheria, Hepatitis B, Rabies), Application (Prophylactic, Therapeutic), Route of Administration, End User, Distribution Channel, Packaging Type - Global Forecast 2025-2030 - Product Image

Hyperimmune Globulin Injection Market by Indication (Diphtheria, Hepatitis B, Rabies), Application (Prophylactic, Therapeutic), Route of Administration, End User, Distribution Channel, Packaging Type - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Intravenous human immunoglobulin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Intravenous human immunoglobulin Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 99 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.